JP2020510063A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510063A5
JP2020510063A5 JP2019550605A JP2019550605A JP2020510063A5 JP 2020510063 A5 JP2020510063 A5 JP 2020510063A5 JP 2019550605 A JP2019550605 A JP 2019550605A JP 2019550605 A JP2019550605 A JP 2019550605A JP 2020510063 A5 JP2020510063 A5 JP 2020510063A5
Authority
JP
Japan
Prior art keywords
compound
formula
salt
reaction conditions
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019550605A
Other languages
English (en)
Japanese (ja)
Other versions
JP7282039B2 (ja
JP2020510063A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/022547 external-priority patent/WO2018170203A1/en
Publication of JP2020510063A publication Critical patent/JP2020510063A/ja
Publication of JP2020510063A5 publication Critical patent/JP2020510063A5/ja
Application granted granted Critical
Publication of JP7282039B2 publication Critical patent/JP7282039B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019550605A 2017-03-16 2018-03-15 Mk2阻害剤、その合成、およびそれに至るまでの中間体 Active JP7282039B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472024P 2017-03-16 2017-03-16
US62/472,024 2017-03-16
PCT/US2018/022547 WO2018170203A1 (en) 2017-03-16 2018-03-15 Mk2 inhibitors, synthesis thereof, and intermediates thereto

Publications (3)

Publication Number Publication Date
JP2020510063A JP2020510063A (ja) 2020-04-02
JP2020510063A5 true JP2020510063A5 (https=) 2021-04-30
JP7282039B2 JP7282039B2 (ja) 2023-05-26

Family

ID=63523971

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019550605A Active JP7282039B2 (ja) 2017-03-16 2018-03-15 Mk2阻害剤、その合成、およびそれに至るまでの中間体

Country Status (8)

Country Link
US (2) US10894796B2 (https=)
EP (1) EP3596086A4 (https=)
JP (1) JP7282039B2 (https=)
CN (1) CN110678471B (https=)
AU (1) AU2018236290B2 (https=)
CA (1) CA3054826A1 (https=)
MX (1) MX387359B (https=)
WO (1) WO2018170203A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
US11098057B2 (en) * 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
WO2018170200A1 (en) * 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
WO2020236636A1 (en) * 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
CN116670142A (zh) * 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体
WO2023025298A1 (zh) * 2021-08-27 2023-03-02 瑞石生物医药有限公司 喹啉并呋喃衍生物及其用途
EP4464694A4 (en) 2022-01-14 2026-04-01 Shanghai Hansoh Biomedical Co Ltd POLYCYCLIC DERIVATIVE CONTAINING PYRIDINE, ITS PREPARATION PROCESS AND ITS USE
CN116643046B (zh) * 2023-05-30 2025-09-12 南昌市高新区人民医院(南昌大学第一附属医院高新医院) Mk2在癌症恶病质肌肉萎缩中的应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200504898B (en) 2002-12-20 2006-11-29 Pharmacia Corp Acyclic pyrazole compounds
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
EP2223925A1 (en) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase inhibitors
MX2009014247A (es) 2007-07-16 2010-01-28 Novartis Ag Compuestos heterociclicos utiles como inhibidores de mk2.
KR101598397B1 (ko) 2008-04-22 2016-02-29 얀센 파마슈티카 엔.브이. 퀴놀린 또는 이소퀴놀린 치환된 피2엑스7 안타고니스트
WO2011062765A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
ES2546465T3 (es) 2010-10-29 2015-09-23 Pfizer Inc Inhibidores de N1/N2-lactama acetil-CoA carboxilasa
EP2635284B1 (en) * 2010-11-01 2019-12-18 Celgene CAR LLC Heterocyclic compounds and uses thereof
SI2648516T1 (sl) * 2010-12-06 2019-01-31 Aclaris Therapeutics, Inc. Substituirane spojine piridinon-piridinila
JP6189434B2 (ja) 2012-07-10 2017-08-30 アレス トレーディング ソシエテ アノニム ピリミジンピラゾリル誘導体
WO2014011902A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CA2908098A1 (en) 2013-03-15 2014-09-25 Celgene Avilomics Research, Inc. Mk2 inhibitors and uses thereof
CN104177340A (zh) * 2013-05-22 2014-12-03 中国中化股份有限公司 一种新型的喹唑啉(硫)酮类化合物及其用途
WO2015128884A1 (en) 2014-02-27 2015-09-03 Council Of Scientific & Industrial Research Poly-benzimidazole with pyrene and anthracene flourophore
EP3179858B1 (en) * 2014-08-13 2019-05-15 Celgene Car Llc Forms and compositions of an erk inhibitor
RS62017B1 (sr) 2014-09-17 2021-07-30 Celgene Car Llc Mk2 inhibitori i njihova upotreba
US10407422B2 (en) 2015-09-03 2019-09-10 Bristol-Myers Squibb Company Triazolopyridine inhibitors of myeloperoxidase
WO2018170203A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Mk2 inhibitors, synthesis thereof, and intermediates thereto
WO2018170200A1 (en) 2017-03-16 2018-09-20 Celgene Car Llc Heteroaryl compounds useful as mk2 inhibitors
US10882867B2 (en) 2017-03-16 2021-01-05 Celgene Car Llc Forms and compositions of a MK2 inhibitor
US11098057B2 (en) 2017-03-16 2021-08-24 Celgene Car Llc 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5′,6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof
EP3596085A4 (en) 2017-03-16 2020-11-25 Celgene CAR LLC DEUTERATED ANALOGUES OF MK2 INHIBITORS AND THEIR USES
WO2020236636A1 (en) 2019-05-17 2020-11-26 Celgene Car Llc Methods of treating a mk2-mediated disorder
KR20230044446A (ko) 2020-07-24 2023-04-04 브리스톨-마이어스 스큅 컴퍼니 급성 호흡기 장애의 치료 방법
CN116670142A (zh) 2021-02-01 2023-08-29 细胞基因公司 Mk2抑制剂、其合成和其中间体

Similar Documents

Publication Publication Date Title
JP2020510063A5 (https=)
WO2009112677A3 (fr) Dérivés bicycliques de carboxamides azabicycliques, leur préparation et leur application en thérapeutique.
CN1163488C (zh) 制备杀虫剂的新方法
RU2009136445A (ru) Способ получения высокочистого празугрель гидрохлорида
JP2005519932A5 (https=)
JP2012504585A5 (https=)
JP2021512163A5 (https=)
JP2011080079A5 (https=)
JP2012523401A5 (https=)
JP2008505171A5 (https=)
JP2010524927A5 (ja) 化合物2−ヒドロキシ−3−[5−(モルホリン−4−イルメチル)ピリジン−2−イル]1h−インドール−5−カルボニトリルの新規な製造方法
JP2019504840A5 (https=)
JP2018518486A5 (https=)
CN103282355A (zh) α-氨基-γ-丁内酯的制造方法
JP2006523626A5 (https=)
JP2013530948A5 (https=)
RU2009143867A (ru) Способы получения производных n-изобутил-n-(2-гидрокси-3-амино-4-фенилбутил)-пара-нитробензолсульфониламида
JP2009502974A5 (https=)
CA2534003A1 (en) 3-quinuclidinyl-n-biarylamides as nicotinic acetylcholine receptor agonists
JP2005516905A5 (https=)
JP2012526045A5 (https=)
TW201326116A (zh) 2,6-二乙基-4-甲基苯醋酸之製造方法
EP2888250B1 (en) Process for the synthesis of substituted gamma lactams
DE50209490D1 (de) Verfahren zur herstellung von zolpidem
CA2615855A1 (en) 4-chromenonyl-1,4-dihydropyridinecarbonitriles and the use thereof